White Mark Andrew 4
4 · ROCKET PHARMACEUTICALS, INC. · Filed Apr 12, 2023
Insider Transaction Report
Form 4
White Mark Andrew
Chief Medical Officer
Transactions
- Award
Common Stock, par value $0.01
2023-04-04+76,662→ 76,662 total - Award
Stock Option (Right to Buy)
2023-04-04+57,739→ 57,739 totalExercise: $17.41Exp: 2033-04-04→ Common Stock (57,739 underlying)
Footnotes (2)
- [F1]Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
- [F2]This option represents a right to purchase a total of 57,739 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.